Psilocybin, MDMA, Ayahuasca & Other “Mind Medicine” Are Propelling Psychedelic Stocks; Are Any On Your Watch List?
While most are trying to navigate COVID-19, investors are looking to get in on the next big trend. Like marijuana a few years ago, penny stocks offered the “emerging opportunity” to invest in the new trend. Fast-forward to 2020 and now it’s become all about psychedelic stocks. Yes, I’m talking about “mushrooms stocks,” “ayahuasca stocks,” “MDMA stocks,” and plenty of other names. But the best part is that most, if not all are psychedelic penny stocks right now. Some of the big named investors include former cannabis pioneer Bruce Linton and even infamous Shark Tank star Kevin O’Leary.
While this emerging trend is currently in the most infant of infancies, there’s a clear desire for more information about mushroom stocks right now. But what’s the reasoning behind the trend? Science has begun tapping into the central nervous impact that these drugs have on humans.
- Defining The Next Generation Of Coronavirus Stocks: This Company Comes into Focus
- 4 Penny Stocks On Robinhood & WeBull To Buy For Under $4
- Penny Stocks Trading for Beginners 
Whether it’s anxiety, addiction, depression, etc. a slew of scientific trials indicate that psychedelics may be a clear solution and even a cure. Now, investors have gotten involved and companies are beginning to go public. Again, among the most popular public companies are psychedelic penny stocks (for now).
Time To Watch Mushroom Stocks?
Just like the early days of cannabis legalization, we’ve begun to see a trend emerge from our neighbors to the north. There is also growing evidence that U.S. research has shown potential for these psychedelics used in a controlled setting. There’s even the start of a recreational movement. Denver has become the first in the U.S. to actually decriminalize psychedelic mushrooms.
With the emergence of this new trend, it’s important to understand while there are high risks with any new industry, there could also be potential rewards. If marijuana penny stocks were any indication, then psychedelic penny stocks might not be a bad idea to have on the list of penny stocks to watch right now.
Psychedelic Penny Stocks To Watch: Revive Therapeutics
Revive Therapeutics (RVV Stock Report) (RVVTF) has been in the news recently for its work with the drug Bucillamine. The goal is to use it as a potential treatment for infectious diseases including COVID-19. In an update this week, Revive said it aims to submit its FDA IND package in June 2020 and expects to obtain FDA acceptance to proceed to a Phase 3 study. The Company is also seeking to conduct a clinical study with Bucillamine in the treatment of COVID-19 in Canada and is preparing its pre-Clinical Trial Application package to Health Canada.
But there’s another side to Revive and that comes with its previous acquisition of Psilocin Pharma Corp. Psilocin has developed patent-pending formulation and production solutions for the active compound Psilocybin. The process encompassed with its intellectual property cover methods of production of Psilocybin-based formulations. Psilocin has developed formulations which include the Hydroxy Line. According to the company, this line will include PSY-0.1 -Capsules, PSY-0.2-Sublingual Spray, PSY-0.3 -Gel Cap, PSY-0.4/0.5 -Effervescent Tablets, and PSY-0.6-Breath Strips.
The company has said that the “precisely dosed formulations will work with both natural and synthetically derived Psilocybin. It will be targeted for clinical research and subject to U.S. FDA approval in the treatment of depression, anxiety, bipolar disorder, bulimia and anorexia nervosa, and a number of other diseases. Revive also entered into a sponsored research partnership agreement with the University of Wisconsin-Madison.
It is to evaluate novel formulations and drug delivery technology focused on psilocybin-based pharmaceuticals. Under the agreement, Dr. Reed and his research team will evaluate psilocybin-based formulations and the patented Tannin-Chitosan composite drug delivery technology for psilocybin. Revive has an exclusive licensing of this technology with the Wisconsin Alumni Research Foundation.
Psychedelic Penny Stocks To Watch: Numinus Wellness Inc.
Numinus Wellness Inc. (NUMI Stock Report) is the latest entrant to the list of mushroom penny stocks to watch. The company IPOd on May 20th opening at $1CAD. The company went public via a reverse take over, and was formerly Rojo Resources. What’s also of note is that In connection with the Transaction, on March 3, 2020, the company closed a non-brokered private placement of 22,980,000 subscription receipts at a price of $0.25 per Subscription Receipt for gross proceeds of $5,745,000. Needless to say, NUMI stock has taken off on May 20 in light of the recent sector hype.
Numinus offers psychedelic treatments, however, psychedelic therapies are not currently available at our Vancouver center. The company has said that “Once approved by Health Canada and various Colleges, our centre will be ideal places for psychedelic therapies to take place in a safe, controlled therapeutic environment.”
However, during this waiting period, Numinus is tapping its other operating pillars that include Numinus Bioscience and Numinus R&D. Numinus was issued a dealer’s license under the Controlled Substances Act in July 2019. Its Numinus Bioscience specifically, is licensed by Health Canada to test, sell, distribute, and eventually conduct research on psychedelic substances. The biggest question right now is will NUMI stock psych-out investors with the discounted shares or will it ease early concerns and move to new highs before the end of the week?
Psychedelic Penny Stocks To Watch: Champignon Brands
Champignon Brands (SHRM Stock Report) (SHRMF) is another one of the early psychedelic stocks to watch. The company focuses on ketamine for treating PTSD. Currently, the company has 4 subsidiaries aimed at addressing this growing market need. These include Altmed, Novo Formulations, Tassili Life Sciences Corp, and Vitality Superteas.
Earlier this year, the company closed a deal with a Canadian pharmacy chain. According to the company, Champignon will leverage the Pharmacy’s existing infrastructure to distribute or “central fill” ketamine topical prescriptions to a network of Canadian medical and pain/addiction clinics.
“With this arrangement, Champignon boasts complete vertical integration with respect to our rapid onset ketamine treatments and therapies. From novel formulations to product development at a purpose-built GMP and DIN licensed pharmaceutical facility, and now automated prescription fulfillment and on-site compounding infrastructure, we have managed to capture the entire product lifecycle,” commented Gareth Birdsall, CEO of Champignon.
While shares of SHRM stock have soared recently, Wednesday saw the first major pullback in the market. However, given the newfound attention following the NUMI IPO, it could be something the market continues to monitor.
Psychedelic Penny Stocks To Watch: Mind Medicine Inc.
No list of mushroom stocks or psychedelic stocks would be complete without Mind Medicine Inc. (MMED Stock Report) (MMEDF). We actually discussed this company when it first went public earlier this year. The company’s developing two categories of medicine based on psychedelics. These include hallucinogenic therapies and non-hallucinogenic products. Mind Medicine raised $24.2 million ahead of its IPO and has also attracted some interesting investors.
These include Blake Mycoskie, founder of Toms Shoes, Shark Tank’s Kevin O’Leary, as well as the former captain of the ship at Canopy Growth (CGC Stock Report), Bruce Linton. While the penny stock hasn’t seen much of an epic move, it hasn’t fallen too much either. Besides a quick rally in late-April, it’s been mostly a sideways trend since the IPO.
In a recent collaboration with University Hospital Basel’s Liechti Laboratory, it has discovered and filed a patent application in the United States (preserving all worldwide rights). It’s for a neutralizer technology intended to “shorten and stop the effects of an LSD trip during a therapy session”. According to Mind Medicine, this discovery, when further developed, may act as the ‘off-switch’ to an LSD trip.
The company gained exclusive, worldwide rights to technology covered by the recently filed patent application. It was based on inventions previously generated by the Liechti Laboratory in LSD and any future LSD research funded by MindMed. Co-Founder and Co-CEO JR Rahn said, “The innovative and original work of the Liechti Laboratory is a treasure trove of novel data on LSD. We are just at the beginning of several significant discoveries that have the potential to further the application of psychedelics as therapeutic medicines.”